Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26

August 13, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 48/26-27 Our Reference No. 48/26-27 Dear Sir/ Madam, Sub: Business Responsibility & Sustainability Report for Financial Year 2025-26 Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Business Responsibility & Sustainability Report of the Company for Financial Year 2025-26. Thanking You Yours Faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com Business Responsibility and Sustainability Report Glenmark Pharmaceuticals Limited Business Responsibility & Sustainability Reporting SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1 Corporate Identity Number (CIN) of the Listed Entity L24299MH1977PLC019982 2 Name of the Listed Entity Glenmark Pharmaceuticals Limited 3 Year of incorporation 1977 4 Registered office address B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400026, Maharashtra, India 5 Corporate address Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai - 400 099, Maharashtra, India 6 E-mail complianceofficer@glenmarkpharma.com 7 Telephone +91 22 4018 9999 8 Website http://www.glenmarkpharma.com 9 Financial year for which reporting is being done April 1, 2025 to March 31, 2026 10 Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited (NSE) BSE Limited (BSE) 11 Paid-up Capital INR 282.20 Mn 12 Name and contact details (telephone, email address) Ms. Rashmi Khandelwal (with effect from May 30, 2026) of the person who may be contacted in case of any Mr. Harish Kuber (Till May 29, 2026) queries on the BRSR report Company Secretary & Compliance Officer complianceofficer@glenmarkpharma.com +91 22 4018 9999 13 Reporting boundary The disclosure under this BRSR is on a standalone* basis unless otherwise stated 14 Name of assurance provider DNV Business Assurance India Private Limited 15 Type of assurance obtained Reasonable level of assurance for BRSR core indicators *Standalone pertains to Glenmark Pharmaceuticals Limited India II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. Description of % of Turnover Description of Business Activity No. Main Activity of the entity 1 Pharmaceuticals The Company specializes in research & development, 100% 100% manufacturing, and sales of a diverse range of pharmaceutical products, including branded generics, generics, specialty medications, and over the counter (OTC) treatments. The Company’s expertise spans across multiple therapeutic areas, including dermatology, respiratory health, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infectives, among others. 252 253 Integrated Annual Report FY 2026 Business Responsibility and Sustainability Report 252 253 weivrevO etaroproC stropeR yrotutatS stnemetatS laicnaniF 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): % of total Product/Service NIC Code Turnover No. contributed 1. The Company’s primary products and services, accounting for 90% of its 210 100% turnover, include the research, development, manufacturing, and sale of branded generics, generics, specialty medicines, and over the counter (OTC) pharmaceutical products. These offerings span a wide range of therapeutic areas such as dermatology, respiratory care, oncology, cardiology, diabetes management, gynecology, gastroenterology, and anti-infective treatments, among others. III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location* Number of plants Number of offices Total National 8 19 27 International 3 48 51 * Includes warehouses ** The disclosure is based on consolidated boundary for Glenmark Pharmaceuticals Limited (the Company). In addition to the above offices and plants, the Company has six Research & Development (R&D) centres located in Sinnar, Taloja, Mahape, Lausanne, New York, and Neuchâtel, which are dedicated to driving innovation and advancing the development of new pharmaceutical products. 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 28 states and 8 union territories International (No. of Countries) More than 80 b. What is the contribution of exports as a percentage of the total turnover of the entity? Our products are exported to more than 80 countries and have a strong footprint across the US, Europe, Asia, Russia, and Brazil. Export revenue contributed 57.99% of our total standalone turnover of INR 84,400.99 million, amounting to INR 48,943.34 million. c. A brief on type of customers Glenmark Pharma serves a diverse and international clientele through its extensive pharmaceutical portfolio, which encompasses essential therapeutic areas including dermatology, respiratory health, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infectives. The primary customers of the Company consist of healthcare professionals, hospitals, government wholesalers, distributors, and retail pharmacy outlets. These entities enable access to the Company’s branded, generic, and specialty pharmaceutical products, catering to a wide range of patient needs in both acute and chronic therapies. The Company functions through a strong distribution network that spans both domestic and international markets, bolstered by its subsidiaries and third-party distributors. Through this multi-channel and geographically diverse presence, the Company provides services to patients and healthcare systems throughout India and various global markets, ensuring that its offerings are in line with local healthcare demands and regulatory standards. Business Responsibility and Sustainability Report Glenmark Pharmaceuticals Limited IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled) S. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 12,312 11,371 92% 941 8% 2. Other than Permanent (E) 396 326 82% 70 18% 3. Total employees (D + E) 12,708 11,697 92% 1,011 8% WORKERS 4. Permanent (F) 2,016 1,941 96% 75 4% 5. Other than Permanent (G) 3,058 2,707 89% 351 11% 6. Total workers (F + G) 5,074 4,648 92% 426 8% b. Differently abled Employees and workers S. Total Male Female Particulars No (A) No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 68 56 82% 12 18% 2. Other than Permanent (E) - - - - - 3. Total differently abled employees (D + E) 68 56 82% 12 18% DIFFERENTLY ABLED WORKERS 4. Permanent (F) 15 14 93% 1 7% 5. Other than permanent (G) - - - - - 6. Total differently abled workers (F + G) 15 14 93% 1 7% 21. Representation of women: Total No. and percentage of Females (A) No. (B) % (B / A) Board of Directors 9 5 56% Key Management Personnel 4 1 25% 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years): FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent Employees 16% 16% 16% 15% 17% 15% 18% 19% 18% Permanent Workers 17% 29% 17% 17% 19% 17% 15% 6% 15% V. Holding, Subsidiary and Associate Companies (including joint ventures) [Showing first 8,000 characters — download PDF for full document]